Allspring Global Investments Holdings LLC Purchases 5,237 Shares of CVS Health Corporation $CVS

Allspring Global Investments Holdings LLC increased its holdings in shares of CVS Health Corporation (NYSE:CVS) by 3.3% in the 1st quarter, Holdings Channel.com reports. The firm owned 166,163 shares of the pharmacy operator’s stock after acquiring an additional 5,237 shares during the quarter. Allspring Global Investments Holdings LLC’s holdings in CVS Health were worth $12,045,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently added to or reduced their stakes in the business. Vanguard Group Inc. boosted its position in shares of CVS Health by 1.5% in the fourth quarter. Vanguard Group Inc. now owns 120,709,530 shares of the pharmacy operator’s stock valued at $9,579,508,000 after acquiring an additional 1,824,424 shares during the period. State Street Corp raised its position in shares of CVS Health by 2.1% during the fourth quarter. State Street Corp now owns 60,183,743 shares of the pharmacy operator’s stock valued at $4,776,182,000 after buying an additional 1,245,457 shares during the last quarter. Capital International Investors raised its position in shares of CVS Health by 3.4% during the fourth quarter. Capital International Investors now owns 27,592,356 shares of the pharmacy operator’s stock valued at $2,189,793,000 after buying an additional 900,153 shares during the last quarter. Norges Bank bought a new stake in shares of CVS Health in the fourth quarter valued at about $1,666,265,000. Finally, Morgan Stanley grew its position in CVS Health by 6.3% during the fourth quarter. Morgan Stanley now owns 20,373,774 shares of the pharmacy operator’s stock worth $1,616,863,000 after buying an additional 1,211,631 shares in the last quarter. Institutional investors own 80.66% of the company’s stock.

CVS Health Trading Up 2.6%

Shares of CVS Health stock opened at $110.40 on Wednesday. The stock has a market capitalization of $140.87 billion, a P/E ratio of 48.64, a price-to-earnings-growth ratio of 1.05 and a beta of 0.61. The company has a quick ratio of 0.66, a current ratio of 0.87 and a debt-to-equity ratio of 0.78. The company has a 50-day simple moving average of $99.58 and a 200 day simple moving average of $85.58. CVS Health Corporation has a 12-month low of $58.50 and a 12-month high of $110.62.

CVS Health (NYSE:CVS) last released its quarterly earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 EPS for the quarter, beating analysts’ consensus estimates of $2.21 by $0.36. The firm had revenue of $100.43 billion for the quarter, compared to analyst estimates of $94.99 billion. CVS Health had a net margin of 0.72% and a return on equity of 11.88%. The company’s revenue for the quarter was up 6.2% compared to the same quarter last year. During the same period in the previous year, the business earned $2.25 earnings per share. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. Research analysts expect that CVS Health Corporation will post 7.46 earnings per share for the current fiscal year.

CVS Health Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, August 3rd. Investors of record on Thursday, July 23rd will be given a dividend of $0.665 per share. The ex-dividend date is Thursday, July 23rd. This represents a $2.66 annualized dividend and a yield of 2.4%. CVS Health’s dividend payout ratio is 117.18%.

Insider Transactions at CVS Health

In other news, EVP Tilak Mandadi sold 69,551 shares of the company’s stock in a transaction on Friday, May 8th. The stock was sold at an average price of $89.58, for a total transaction of $6,230,378.58. Following the transaction, the executive vice president owned 10,133 shares of the company’s stock, valued at $907,714.14. This represents a 87.28% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Larry Robbins sold 370,462 shares of the company’s stock in a transaction dated Thursday, May 21st. The shares were sold at an average price of $93.45, for a total transaction of $34,619,673.90. Following the transaction, the director owned 4,824,799 shares in the company, valued at approximately $450,877,466.55. The trade was a 7.13% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 3,441,551 shares of company stock worth $323,703,977. Insiders own 0.85% of the company’s stock.

Key Headlines Impacting CVS Health

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS announced that common prescription medications for dogs and cats are now available at its roughly 9,000 CVS Pharmacy locations nationwide, expanding the chain’s role beyond human prescriptions and potentially adding a small but incremental revenue stream while increasing store traffic. Pet medications now available at CVS Pharmacy®
• Positive Sentiment: Market commentary highlighted that CVS has been outperforming the broader market, reflecting continued investor confidence in the company’s ongoing operational improvement and turnaround efforts. CVS Health (CVS) Surpasses Market Returns: Some Facts Worth Knowing
• Positive Sentiment: Another report echoed the same outperformance theme, noting CVS’s strong trading versus the market and suggesting that investors remain focused on the company’s improving fundamentals. CVS Health (CVS) Surpasses Market Returns: Some Facts Worth Knowing
• Neutral Sentiment: A longer-form analysis argued CVS is still in the middle of a meaningful turnaround, with improving margins, declining leverage, and strong cash flow, but it also noted the stock is no longer viewed as a deep bargain after its rally. CVS Health Update: The C- Student Now Pulling Down A B+

Wall Street Analyst Weigh In

A number of analysts have commented on the company. DA Davidson raised their price objective on CVS Health from $80.00 to $100.00 and gave the stock a “buy” rating in a research report on Thursday, May 7th. Morgan Stanley boosted their price objective on CVS Health from $106.00 to $111.00 and gave the company an “overweight” rating in a research report on Thursday, June 4th. Barclays raised their target price on CVS Health from $101.00 to $106.00 and gave the stock an “overweight” rating in a research report on Tuesday, May 26th. Weiss Ratings upgraded shares of CVS Health from a “hold (c)” rating to a “hold (c+)” rating in a research note on Monday. Finally, Truist Financial increased their price objective on shares of CVS Health from $108.00 to $118.00 and gave the company a “buy” rating in a research note on Tuesday, July 14th. Twenty-one analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat, CVS Health presently has an average rating of “Moderate Buy” and an average price target of $105.38.

CVS Health Company Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.